Metabolism of [1-(14)C] and [2-(14)C] leucine in cultured skin fibroblasts from patients with isovaleric acidemia. Characterization of metabolic defects.
Leucine metabolism in cultured skin fibroblasts from patients with isovaleric acidemia was compared with that in normal fibroblasts and in cells from patients with maple syrup urine disease using [1-(14)C] and [2-(14)C] leucine as substrates. Inhibitory effects of methylenecyclopropylacetic acid on leucine metabolism in normal cells were also investigated. Production of 14CO2 from [2-(14)C] leucine was very reduced (96-99%) in both types of mutant cells. Radioactive isovaleric acid accumulated in assay media with isovaleric acidemia cells but not in those with maple syrup urine disease cells. Unexpectedly, 14CO2 production from [1-(14)C] leucine was partially depressed (80%) in isovaleric acidemia cells whereas in maple syrup urine disease cells it was strongly depressed (99%) as expected. These two mutant cells were clearly distinguished by detection of 14C-isovaleric acid accumulation after incubation with [2-(14)C] leucine. A pattern of inhibition of leucine oxidation similar to that seen in isovaleric acidemia cells was induced in normal cells by the addition of 0.7 mM methylenecyclopropylacetic acid to the assay medium. The partial inhibition of [1-(14)C] leucine oxidation seen in isovaleric acidemia cells and also in normal cells in the presence of the inhibitor appears to be, at least in part, due to an accumulation of isovalerate in the cells. Isovaleric acid (5-10) mM) inhibited [1-(14)C] leucine oxidation 32-68% when added to the assay medium with normal cells. Addition of flavin adenine dinucleoside to culture medium or assay medium or both did not restore oxidation of either leucine substrate in isovaleric acidemia cells.
D008456:2-Methyl-4-chlorophenoxyacetic Acid / Q000494:pharmacology; D000592:Amino Acid Metabolism, Inborn Errors / Q000378:metabolism*; D002245:Carbon Dioxide / Q000096:biosynthesis; D002460:Cell Line; D002478:Cells, Cultured; D003864:Depression, Chemical; D005347:Fibroblasts / Q000378:metabolism; D005182:Flavin-Adenine Dinucleotide / Q000494:pharmacology; D005998:Glycine / Q000031:analogs & derivatives / Q000378:metabolism; D006801:Humans; D007930:Leucine / Q000378:metabolism*; D008375:Maple Syrup Urine Disease / Q000378:metabolism / Q000473:pathology; D010084:Oxidation-Reduction / Q000187:drug effects; D012867:Skin / Q000378:metabolism; D013386:Succinates / Q000378:metabolism; D014631:Valerates / Q000378:metabolism* / Q000494:pharmacology; D014633:Valine / Q000378:metabolism
D013386:Succinates; D014631:Valerates; D002245:Carbon Dioxide; D005182:Flavin-Adenine Dinucleotide; D008456:2-Methyl-4-chlorophenoxyacetic Acid; D007930:Leucine; D014633:Valine; D005998:Glycine